Sarepta Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Private, Public
- Established
- 1980-01-01
- Employees
- 1.3K
- Market Cap
- $13.4B
- Website
- http://www.sarepta.com
- Introduction
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04626674
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
- Conditions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 241
- Registration Number
- NCT04475926
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Arkansas Children's, Little Rock, Arkansas, United States
🇺🇸University of California San Diego, La Jolla, California, United States
Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT04004065
- Locations
- 🇮🇹
A.O.U. Citta della Salute e della Scienza di Torino - SS Malattie Neuromuscolari, Department of Neurosciences, Torino, Italy
🇳🇱Leiden University Medical Center, Leiden, Netherlands
🇪🇸Hospital Sant Joan de Déu. U.B., Barcelona, Spain
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT03992430
- Locations
- 🇮🇳
Royal Institute of Child Neurosciences, Ahmedabad, India
🇩🇪Charité Universitätsmedizin Berlin CVK, Berlin, Germany
🇮🇳Aster RV Hospital, Bengaluru, India
A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03985878
- Locations
- 🇫🇷
Hopital Trousseau, Bâtiment lemariey, Paris, France
🇧🇪UZ-Gent, Gent, Belgium
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli, UOC Neuropsichiatria Infantile, Rome, Italy
A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03769116
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03675126
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States
Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03652259
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT03532542
- Locations
- 🇮🇹
Fondazione Policlinico Universitario A Gemelli, Milano, Italy
🇧🇪UZ Leuven, Leuven, Belgium
🇺🇸Children's Hospital of Wisconsin, Corporate Center Suite 540, Milwaukee, Wisconsin, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03375255
- Locations
- 🇺🇸
Neuromuscular Research Center, Sacramento, California, United States
🇺🇸Rare Disease Research, LLC, Atlanta, Georgia, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States